UBS Group AG Has $2.60 Million Stake in Invivyd, Inc. $IVVD

UBS Group AG raised its position in shares of Invivyd, Inc. (NASDAQ:IVVD) by 683.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,050,923 shares of the company’s stock after buying an additional 916,842 shares during the period. UBS Group AG owned about 0.45% of Invivyd worth $2,596,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. RA Capital Management L.P. acquired a new stake in shares of Invivyd during the third quarter worth approximately $18,831,000. ADAR1 Capital Management LLC acquired a new stake in shares of Invivyd during the third quarter worth approximately $8,108,000. Vanguard Group Inc. increased its holdings in shares of Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after buying an additional 1,834,970 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Invivyd by 15.8% during the third quarter. Millennium Management LLC now owns 1,446,615 shares of the company’s stock worth $1,591,000 after buying an additional 197,522 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Invivyd during the third quarter worth approximately $894,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Price Performance

Shares of Invivyd stock opened at $1.10 on Wednesday. The firm has a 50 day simple moving average of $1.42 and a 200 day simple moving average of $1.87. Invivyd, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm has a market cap of $324.07 million, a P/E ratio of -3.55 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, May 14th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%.The business had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million. On average, sell-side analysts expect that Invivyd, Inc. will post -0.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on IVVD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Wednesday, April 29th. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Invivyd in a report on Monday, May 18th. Wall Street Zen lowered shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Invivyd in a report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.